Illumina, Illumavista Settle Trademark Infringement Suit | GenomeWeb

Illumina has asked a federal court to dismiss a six-month-old trademark infringement lawsuit against Illumavista Biosciences following an apparent out-of-court settlement.

The San Diego firm filed a notice of dismissal on May 9 with the US District Court for the Western District of Wisconsin, according to court documents. Illumina said it had been discussing a settlement with on Madison, Wis.-based Illumavista in several other documents.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.